Aurinia Pharmaceuticals News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Trading-Depot	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Trading-Depot

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

02.05.23	Aurinia Pharmaceuticals Announces Swissmedic Approval of LUPKYNIS® (voclosporin) (Businesswire)
28.04.23	Glass Lewis Recommends Aurinia Shareholders Vote "FOR” ALL Company Director Nominees at 2023 Annual Meeting (Businesswire)
25.04.23	Toni Braxton and Aurinia Want People with Lupus Nephritis to Get Uncomfortable to Protect their Kidneys (Businesswire)
24.04.23	Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 4, 2023 (Businesswire)
11.04.23	Aurinia Pharmaceuticals Announces New and Refined Method of Use Patent for LUPKYNIS® in the Treatment of Lupus Nephritis Issued by United States Patent and Trademark Office (Businesswire)
05.04.23	Aurinia Pharmaceuticals Announces Promising Topline Data from Renal Biopsy Sub-study of the AURORA Trial (Businesswire)
03.04.23	Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
06.03.23	Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
28.02.23	Aurinia Reports Fourth Quarter and Full Year 2022 Financial Results and Company Updates (Businesswire)
24.02.23	Aurinia Pharmaceuticals to Present at Upcoming Investor Healthcare Conference (Businesswire)
07.02.23	Aurinia Pharmaceuticals to Release Fourth Quarter and Full Year Financial and Operational Results on February 28, 2023 (Businesswire)
06.02.23	Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
25.01.23	Aurinia Announces PTAB Has Terminated Inter Partes Review (Businesswire)
24.01.23	Aurinia Pharmaceuticals Announces Allowance of a New and Refined Method of Use Patent for LUPKYNIS® in the Treatment of Lupus Nephritis From the United States Patent and Trademark Office (Businesswire)
06.01.23	Aurinia Provides Preliminary Unaudited Fourth Quarter and Full-year 2022 Net Revenue Results (Businesswire)
04.01.23	Aurinia Pharmaceuticals to Present at Upcoming 41st Annual J.P. Morgan Healthcare Conference (Businesswire)
03.01.23	Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
03.01.23	Aurinia Announces LUPKYNIS® (voclosporin) Patent Challenge Settlement Reached With Sun Pharmaceuticals (Businesswire)
05.12.22	Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
30.11.22	Aurinia Announces the Great Britain Marketing Authorization of LUPKYNIS® (voclosporin) for the Treatment of Lupus Nephritis (Businesswire)
03.11.22	Aurinia Reports Third Quarter and Nine Months 2022 Financial and Operational Results (Businesswire)
28.10.22	Aurinia Pharmaceuticals to Release Third Quarter 2022 Financial and Operational Results on November 3, 2022 (Businesswire)
27.10.22	Aurinia Pharmaceuticals Announces Presentations at American Society of Nephrology (ASN) Kidney Week 2022 (Businesswire)
03.10.22	Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Swiss Re	145.50	2.36 %	K V
Swiss Life Hldg	846.80	1.75 %	K V
ABB	56.98	1.35 %	K V
Zurich Insur Gr	560.80	1.34 %	K V
Swisscom	581.50	0.87 %	K V
Alcon	58.76	-0.14 %	K V
Roche Hldg G	254.60	-0.16 %	K V
Part Grp Hldg	1’027.50	-0.34 %	K V
Logitech Intl	86.36	-0.60 %	K V

Aurinia Pharmaceuticals Aktie VALOR 22686530 / ISIN CA05156V1022

Nachrichten zu Aurinia Pharmaceuticals Inc

Aktien Top/Flop

Meistgelesene Nachrichten